Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

NCT07499271 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions

DRUG: POLA-R-CHP
DRUG: Orelabrutinib

Sponsor

The First Affiliated Hospital of Soochow University